for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Celldex’S Metric Study In Metastatic Triple-Negative Breast Cancer Does Not Meet Primary Endpoint

April 16 (Reuters) - Celldex Therapeutics Inc:

* CELLDEX’S METRIC STUDY IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER DOES NOT MEET PRIMARY ENDPOINT

* CELLDEX THERAPEUTICS INC - GLEMBATUMUMAB VEDOTIN SAFETY PROFILE WAS CONSISTENT WITH PRIOR EXPERIENCE

* CELLDEX THERAPEUTICS INC - EVALUATING OUR OPERATIONAL AND WORKFORCE NEEDS TO EXTEND OUR FINANCIAL RESOURCES

* CELLDEX THERAPEUTICS INC - RANDOMIZED, PHASE 2B METRIC STUDY OF GLEMBATUMUMAB VEDOTIN COMPARED TO XELODA FAILED TO MEET ITS PRIMARY ENDPOINT

* CELLDEX THERAPEUTICS INC - NO SIGNIFICANT ADVANTAGE FOR GLEMBATUMUMAB VEDOTIN IN KEY SECONDARY ENDPOINTS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up